Answers are grounded in this paper and cite their sources.
Objective: Renal manifestations in COVID-19 cases range from proteinuria to AKI, while COVID-19 mortality is linked to alveolar injury; renal involvement associates with diverse outcomes, including elevated mortality. The aim of this study was to compare COVID-19 infected patients with and without Chronic Kidney Disease (CKD), analyzing clinical and lab differences, acute kidney injury rates, and renal manifestations' impact on outcomes. Methods: This prospective cohort study was conducted across three COVID-19 centers: Al-Imamain Al-Kadhimain Medical City, Al-Karamu Hospital, and Dar Al-Salam Hospital, from January to July 2021. The cohort included 100 confirmed COVID-19 infected patients, followed until discharge, recovery, or death. Two groups were defined: Group A (CKD) with documented chronic kidney disease and COVID-19, and Group B (non-CKD) without prior renal disease. Data collection encompassed demographics, medical history, radiological and biochemical data, clinical renal indicators, COVID-19 severity, urine analysis, and development of AKI. Results: In this study involving 100 participants (33 CKD, 67 non-CKD), age differences were significant (p = 0.003), with CKD patients being older. COVID-19 severity and survival rates varied significantly (both p < 0.001) between study groups. Renal manifestations including proteinuria, hematuria, pyuria polyuria, oliguria, and anuria occurred more frequently in the CKD group but only proteinuria and oliguria reached statistical significance (p < 0.05). Male gender, proteinuria, hematuria, and AKI development were linked to heightened mortality risk. Lower hemoglobin, lymphocyte counts, and elevated D-dimer indicated CKD impact. Hypertension was significantly associated with AKI risk (p = 0.031). Conclusion: The study highlighted that age, male gender, and comorbidities like hypertension predicted COVID-19 severity and mortality. Renal indicators, notably proteinuria, hematuria, and AKI, were significant markers of increased mortality risk.
No takes yet. Share an insight, caveat, or question.
Manuti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: